Antineutrophil Cytoplasmic Antibody and Multiple Sclerosis

Jason C. George¹, Prince Mohan¹ and Kevin Ho¹

¹Department of Nephrology, Geisinger Medical Center, Danville, Pennsylvania, USA

Correspondence: Jason C. George, Department of Nephrology, Geisinger Medical Center, 100 North Academy Avenue, Danville, Pennsylvania 17821, USA. E-mail: jcgeorge@geisinger.edu

Kidney Int Rep (2018) 3, 732–737; https://doi.org/10.1016/j.ekir.2017.11.013
© 2017 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

INTRODUCTION

Antineutrophil cytoplasmic antibody (ANCA)—associated pauci-immune crescentic glomerulonephritis (PICGN) is a well-known entity that occurs in approximately 7 to 10 people per million per year in the United States.¹ Its presentation can be highly variable, ranging from subacute kidney injury to a rapidly progressive glomerulonephritis. With a typical onset during the fifth to seventh decade of life, it can be associated with an 80% 1-year mortality if left untreated, leading to rapid progression and end-stage renal disease in many patients without prompt diagnosis and intervention with appropriate immunosuppression.¹,² ANCA.s are predominantly IgG autoantibodies directed against the primary granules of lysosomes in certain immune cells and are present in approximately 80% of patients with pauci-immune necrotizing vasculitis.³ They are known to exist in association with inflammatory demyelinating diseases (IDD), such as multiple sclerosis (MS), optic neuritis, and neuromyelitis optica. In the context of IDD, few studies to date have described the clinical importance of ANCA, and associated renal disease has not been previously reported. We present a case of ANCA-associated PICGN occurring in a patient with a history of MS/optic neuritis.

CASE PRESENTATION

Clinical History and Pertinent Laboratory Data

A 55-year-old woman of white ethnicity with a history of MS in her usual state of health developed subacute kidney injury as seen on routine laboratory tests (creatinine 3.0 mg/dl from baseline of 0.6 mg/dl 9 months prior). She had no personal or family history of kidney disease and denied fevers, chills, joint pain, gross hematuria, rash, cough, and hemoptysis. Physical examination at the time of the nephrology clinic evaluation included a blood pressure of 162/98 mm Hg. Additional pertinent examination findings included +2 pitting edema of the lower extremities bilaterally. Additional laboratory tests showed blood urea nitrogen (BUN) of 26 mg/dl, serum albumin of 3.6 mg/dl, and mild hypokalemia (Table 1). Urinalysis showed microscopic hematuria (50+ red blood cells per high power field) with spot urine protein/creatinine ratio of 3.34 g/g. Serology showed perinuclear ANCA (p-ANCA) positivity with a confirmative antmyeloperoxidase (MPO) titer of 32.4. Pertinent negative laboratory values included cytoplasmic ANCA (C-ANCA), antinuclear antibody (ANA), hepatitis C antibody, HIV antigen/antibody, serum/urine protein electrophoresis, and normal complement levels. Renal ultrasound showed normal kidney size and echogenicity without calculi or hydronephrosis.

Renal Biopsy Findings

Renal biopsy was performed, and 25 glomeruli were presented for light microscopy. A total of 12 glomeruli showed cellular or fibrocellular crescents with fibrin deposition (Figure 1). Significant interstitial inflammation with eosinophils was noted, as well as mild tubular atrophy/interstitial fibrosis (Figure 2). Immunofluorescence showed strong fibrinogen staining in fibrocellular crescents, trace positivity for IgG and IgM, but was negative for IgA, C3, C1q, kappa (k) and lambda (λ) (Figure 3). Electron microscopy showed focal epithelial foot process effacement, focal basement membrane thickening, and mesangial sclerosis.

Clinical Course and Follow-up

Treatment with methylprednisolone 1 g i.v. daily for 3 days was completed, followed by oral prednisone 1 mg/kg daily. She was subsequently treated with rituximab 375 mg/m² i.v. weekly for 4 weeks. Of note, her MS had been diagnosed 10 years prior after an episode of acute right-sided optic neuritis. She was
treated with prednisone initially and then interferon-β 1b (IFN-β 1b) therapy for 10 years with good response. She developed disease progression with new white matter lesions on brain magnetic resonance imaging and was transitioned to teriflunomide therapy approximately 1 month before her kidney injury. Approximately 6 months after her initial kidney injury and 3.5 months after completion of weekly rituximab therapy, her renal function and proteinuria showed marked improvement, and repeat MPO testing was normal.

**DISCUSSION**

ANCAs target specific cytoplasmic proteins of neutrophils and monocytes in mediation of disease. Major antigenic targets include MPO and proteinase-3 (PR3). MPO-ANCAs are typically more frequent in microscopic polyangiitis (MPA), whereas PR3-ANCA are more common in granulomatosis with polyangiitis (GPA).

The immune pathogenic effects of ANCA in renal vasculitis have been well demonstrated in animal models. In addition to the kidney, ANCAs can potentially involve the central nervous system (CNS) as part of their systemic pathogenic effects. MS is a well-known and potentially debilitating condition associated with demyelination and chronic inflammation in the CNS white matter. Extensive data from animal models suggest that its pathogenesis is related to an autoimmune process involving T and B lymphocytes and pro-inflammatory cytokines.

ANCAs positivity in IDD is known to occur, with a reported incidence of 1% to 7% in retrospective and prospective studies. The autoimmunity of ANCA with respect to IDD and their clinical significance have previously been investigated. In a series of 13 patients with clinically definite MS as well as acute transverse myelopathy and severe optic neuropathy,

| Laboratory value | Day 0 | 6 mo | Reference range |
|------------------|-------|------|-----------------|
| BUN (mg/dl)      | 26    | 27   | 6-20            |
| Creatinine (mg/dl) | 3.0  | 1.4  | 0.5-1.0         |
| Sodium (mg/dl)   | 137   | 140  | 135-146         |
| Potassium (mg/dl)| 3.2   | 2.9  | 3.5-5.1         |
| Chloride (mg/dl) | 95    | 96   | 98-107          |
| CO₂ (mg/dl)      | 27    | 29   | 22-32           |
| Anti-MPO (units) | 32.4  | 13.6 | <20.1           |
| Albumin (g/dl)   | 3.6   | 3.8  | 3.8-5.0         |
| Urine protein/creatinine ratio (g/g) | 3.34 | 1.37 | <0.150         |
| Complement C3 (mg/dl) | 108 | -    | 90-180          |
| Complement C4 (mg/dl) | 22  | -    | 10-40           |
| ANA              | <40   | -    | <40             |
| Hepatitis C antibody | Negative | -    | Negative        |
| HIV antigen/antibody | Negative | -    | Negative        |
| Serum protein electrophoresis | Negative | -    | Negative        |
| C-ANCA           | Negative | -    | Negative        |

ANA, antinuclear antibody; BUN, blood urea nitrogen; C-ANCA, cytoplasmic anti-neutrophil cytoplasmic antibodies; MPO, antimyeloperoxidase.
Fukazawa et al. investigated ANCA serology and found p-ANCA positivity in 46.2% of patients with the optic–spinal form of MS, compared to 0% in those with conventional MS or acute transverse myelopathy (P = 0.0005).6 These data suggest that the presence of ANCA in IDD is not an epiphenomenon but could play a direct role in disease pathogenesis in certain forms of MS. The largest clinical series of ANCA in CNS demyelinating disorders further supported such findings and investigated their clinical significance. Long et al. retrospectively investigated 269 patients with IDD who were positive for ANCA and reported 9.5% and 2.3% positivity rates for p-ANCA and c-ANCA, respectively.6 Patients with spinal cord lesions were more likely to test positive for ANCA. In addition, ANCA-positive patients were older, had longer spinal cord lesions, and had more symptoms of disability at baseline, suggesting an association with worse clinical outcomes in MS patients.6 Spadaro also reported circulating ANCA in 7 of 105 MS patients with various stages of disease.7 In addition, Nakashima et al. examined sera from 98 patients with various CNS disorders, including MS, myelitis, and viral-associated myelopathy, and found p-ANCA in 5 patients, including 2 with MS, and all of whom had subacute myelopathy of varying severity.9 Overall, these data suggest that ANCAs can not only be present in the context of IDD but can potentially have an association with varying disease severity and clinical outcomes. However, studies investigating the relationship between ANCAs and response to therapy in IDD and risk of ANCA-associated renal disease in such patients are currently lacking.

Investigation of the pathogenic role of ANCAs in various disease processes has become more extensive. The mechanism by which ANCAs exert their effects is not fully understood, but is believed to be related to complex interactions with neutrophils, monocytes, and vascular endothelial cells. Previous studies have suggested that ANCAs indirectly induce a pro-inflammatory state via stimulation of neutrophils to undergo a burst release of reactive oxygen species, subsequently leading to degranulation.10 To exert their pro-inflammatory effects, ANCAs must recognize and bind their target antigens (i.e., MPO and PR3). This is accomplished via internalization of the ANCAs by neutrophils or by making the antigens more accessible on the neutrophil surface. When neutrophils are activated by various pro-inflammatory factors, MPO and PR3 translocate from the cytoplasm to the surface of the cell in a process termed priming.11,12 This neutrophil priming is essential for ANCAs to exert their pathogenic effects, involves various pro-inflammatory mediators (such as tumor necrosis factor [TNF] and interleukin-6), and has been demonstrated in vitro.13 Such molecular events can be triggered by certain infectious stimuli and can precede the clinical manifestations of ANCA-associated disease.12 Cross-linking of ANCAs with Fc receptors on neutrophils stimulates degranulation and an oxidative burst, which contributes to the development of vasculitis.11,12 Both ANCA phenotypes (cytoplasmic and myeloperoxidase-specific) can induce cytokine-primed neutrophil activation and the release of primary granule contents in a dose-dependent manner.10,13,14 TNF-α, a pro-inflammatory cytokine, has also been shown to have a role in the pathogenesis of ANCA-associated disease and can enhance ANCA-induced neutrophil activation.15 This is thought to be related to increased expression of MPO and PR3 antigens on the surface of unprimed neutrophils after exposure to TNF-α, allowing for increased binding to autoantibodies.16 Treatment with IFN-β 1b has been shown to decrease CD3-mediated TNF-α secretion from mononuclear cells.17 Interestingly, this patient developed ANCA-mediated glomerular injury 1 month after discontinuing IFN-β 1b therapy, suggesting that unopposed TNF-α secretion may have played a role in the pathogenesis. In addition to PICGN, the renal biopsy sample showed interstitial nephritis, which can occur in the setting of ANCA-associated renal disease, as the immunologic affects are widespread and can involve not only the glomerular microvasculature but all compartments of the kidney.18 Acute interstitial nephritis due to teriflunomide therapy was also in the differential diagnosis. However, given the positive MPO-ANCAs and crescents seen on the renal biopsy sample, the patient’s clinical picture was more consistent with an ANCA-mediated PICGN.

More recent data in animal models suggest that ANCAs play a more direct role and that the presence of anti-MPO alone is enough to induce a PICGN, even in the absence of functional T and B-lymphocytes.3 In vivo evidence to suggest a direct pathogenicity of ANCAs in murine models has been demonstrated. Immunization of MPO knockout mice with mouse-MPO and transfer of anti-MPO splenocytes to wild-type mice and those lacking functional B and T cells elicits a severe, necrotizing glomerulonephritis.3,19 Despite these data, evidence for direct pathogenicity of ANCAs has been questioned. This is partly due to the fact that healthy individuals can also have natural circulating autoantibodies against MPO and PR3. However, compared with pathogenic ANCAs, studies have shown that these “natural” autoantibodies occur in lower titers, have lower antigen avidity, have less subclass diversity, and are less capable of inducing a neutrophil respiratory burst in vitro.19,20 Earlier data have shown that MPO-ANCAs target not only a single epitope but,
rather, a small number of different epitope regions. A more recent study examining MPO epitope specificity using high-sensitivity epitope excision and mass spectrometry identified 12 specific MPO epitopes that were present exclusively in patients with active disease and 8 that were present in healthy subjects. MPO-ANCAs directed against 1 linear epitope were exclusively associated with active disease, and reactivity to this epitope declined with disease remission. These findings provide helpful insight into the questions regarding the true pathogenicity of ANCs. If only a specific subgroup of ANCs are pathogenic, then the presence of similar natural autoantibodies in healthy individuals does not refute the role of ANCs as pathogenic.

Based on the paucity of Ig and complement deposition that is classically seen in ANCA-associated glomerulonephritis, these mediators have traditionally not been implicated in the pathogenesis of ANCA-associated vasculitis (AAV). However, emerging data in animal models and clinical observations over the past decade suggest that activation of complement, particularly the alternative complement pathway, plays a crucial role in the development of AAV. The alternative complement pathway, unlike the classical and lectin pathways, is constitutively active and is characterized by spontaneous hydrolysis of complement C3 in the fluid phase rather than on a cell membrane surface. Such a “tick-over” mechanism allows for a low level and steady state of complement activation that does not have any consequences under normal physiologic conditions. Complement C5a, 1 of the end products of the alternative complement pathway, acts as a chemoattractant molecule that can recruit various types of inflammatory cells, such as neutrophils, eosinophils, monocytes, and T-cells. Such a role of complement activation has been implicated in the pathogenesis of AAV. For example, in an experimental murine model of MPO-ANCA, mice deficient in C5 that were pretreated with cobra venom factor to deplete complement failed to develop glomerulonephritis and vasculitis. AAV development in wild-type and C4-deficient mice was comparable, whereas C5-deficient mice were protected from disease. In human studies, various complement components have been detected in renal biopsy samples of patients with pauci-immune ANCA-associated glomerulonephritis, including C5b-C9, C3d, and factor B with co-localization in active glomerular lesions. Additional studies have shown a positive correlation between deposition of activated factor B (Bb), an essential serine esterase of the alternative complement pathway, and the proportion of cellular crescents, degree of interstitial infiltrate, degree of interstitial fibrosis/tubular atrophy, and an inverse correlation with the number or normal glomeruli. In addition, urinary levels of Bb, C3a, C5a, and soluble C5b-9 were significantly higher in active disease compared to those in remission. Such findings lend evidence to the importance of complement activation in the mediation of ANCA-associated disease. Prior to these observations, the role of complement in the pathogenesis of ANCA vasculitis was not widely recognized, in part due to the lack of complement deposition in the vessel walls in AAV and ANCA-associated PICGN. However, compelling evidence in animal models suggests that the lack of obvious complement and Ig deposition at high levels does not refute its role in the pathogenesis of ANCA-associated disease. The role of complement activation in the pathogenesis of MS has also been suggested by animal models as well as retrospective data in MS patients. For example, in a systematic immunohistochemical analysis of 17 patients with progressive MS and longstanding disease (mean duration 26 ± 12 years), immune labeling of MS plaques in brain and spinal cord were consistently positive for complement proteins, activators, and regulatory factors (C3, factor B, C1q, C4d, MAC, factor H, C1-inhibitor, clusterin), implicating their role in the pathogenesis of axonal and myelin injury in MS patients. This combination of evidence highlights the importance of complement activation in the pathogenesis of both PICGN and IDD and why the potential for concomitant ANCA-associated renal disease in MS patients should not be overlooked.

The potential similarities in pathogenesis of PICGN and IDD may have their roots in a genetic basis. Several genome-wide association studies have provided helpful insight into the common genetic variants that are shared among several important autoimmune conditions, including type 1 diabetes mellitus (T1D), Graves disease, MS, Crohn disease, and GPA. CD226, an important cell membrane–associated protein that is involved in T-cell adhesion and costimulation, belongs to the Ig supergene family of receptors and is expressed on most CD4+, CD8+ and natural killer cells. It is involved in the regulation of T-cell activation and expansion. In autoimmune encephalomyelitis, an animal model of brain inflammation similar to MS, anti-CD226 monoclonal antibody has been shown to delay the onset and reduce the severity of T-cell–mediated autoimmune disease. Furthermore, Gly307Ser, a single nucleotide polymorphism located in the CD226 gene on chromosome 18q22 has shown a significant association with T1D, MS, and rheumatoid arthritis in large panels of populations of white ethnicity. In a separate study evaluating the impact of the CD226 Gly307Ser single-nucleotide polymorphism on the etiology and
pathology of GPA, genotyping showed a significant association of the minor allele 307Ser with GPA in a large panel of German patients compared with ethnically matched healthy controls. This was in addition to replicating the association between 307Ser and MS in a similar patient population.

In conclusion, given the known autoimmune and pro-inflammatory mechanisms of these conditions, this case offers some important teaching points (Table 2) and an interesting hypothesis: that the presence of ANCA in patients with underlying demyelinating disease can influence susceptibility to clinically significant renal disease. However, future studies are needed to substantiate such a potential correlation.

### DISCLOSURE

KH disclosed a research and financial relationship with Sanofi-Genzyme. The other authors declared no competing interests.

### ACKNOWLEDGMENTS

Presented in part at the National Kidney Foundation Annual Meeting, April 18–22, 2017, Orlando, FL.

### REFERENCES

1. Syed R, Rehman A, Valecha G, El-Sayegh S. Pauci-immune crescentic glomerulonephritis: An ANCA-associated vasculitis. *Biomed Res Int*. 2015;2015:402826.  
2. Rowaiye OO, Kusztal M, Klinger M. The kidneys and ANCA-associated vasculitis: from pathogenesis to diagnosis. *Clin Kidney J*. 2015;8:343–350.  
3. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. *J Clin Invest*. 2002;110:955–963.  
4. Furuta S, Jayne DRW. Antineutrophil cytoplasm antibody-associated vasculitis: recent developments. *Kidney Int*. 2013;84:244–249.  
5. Hemmer B, Cepok S, Nessler S, Sommer N. Pathogenesis of multiple sclerosis: an update on immunology. *Curr Opin Neurol*. 2002;15:227–231.  
6. Long Y, Zheng Y, Chen M, et al. Antineutrophil cytoplasmic antibodies in patients with idiopathic inflammatory-demyelinating diseases. *Neuroimmunomodulation*. 2014;21:297–303.  
7. Spadaro M, Amendolea MA, Mazzucconi MG, et al. Autoimmunity in multiple sclerosis: study of a wide spectrum of autoantibodies. *Mult Scler*. 1999;5:121–125.  
8. Fukazawa T, Hamada T, Kikuchi S, et al. Antineutrophil cytoplasmic antibodies and the optic-spinal form of multiple sclerosis in Japan. *J Neurol Neurosurg Psychiatry*. 1996;61:203–204.  
9. Nakashima I, Fujihara K, Endo M, et al. Clinical and laboratory features of myelitis patients with anti-neutrophil cytoplasmic antibodies. *J Neurol Sci*. 1998;157:60–66.  
10. Savage CO. ANCA-associated renal vasculitis. *Kidney Int*. 2001;60:1614–1627.  
11. Chen M, Jayne DRW, Zhao M. Complement in ANCA-associated vasculitis: mechanisms and implications for management. *Nat Rev Nephrol*. 2017;13:359–367.  
12. Ketritz R. How anti-neutrophil cytoplasmic autoantibodies activate neutrophils. *Clin Exp Immunol*. 2012;169:220–228.  
13. Falk RJ, Terrell RS, Charles LA, Jennette JC. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. *Proc Natl Acad Sci U S A*. 1990;87:4115–4119.  
14. Falk RJ. ANCA-associated renal disease. *Kidney Int*. 1990;38:998–1010.  
15. Huugen D, Tervaert JWC, Heeringa P. TNF-alpha bioactivity-inhibiting therapy in ANCA-associated vasculitis: clinical and experimental considerations. *Clin J Am Soc Nephrol*. 2006;1:1100–1107.  
16. Hess C, Sadallah S, Schifferli JA. Induction of neutrophil responsiveness to myeloperoxidase antibodies by their exposure to supernatant of degranulated autologous neutrophils. *Blood*. 2000;96:2822–2827.  
17. Brod SA, Marshall GDJ, Henninger EM, et al. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. *Neurology*. 1996;46:1633–1638.  
18. Nakamura N, Yaegaki M, Sugawara T, et al. Acute tubulointerstitial nephritis with antineutrophil cytoplasmic antibody. *Hong Kong J Nephrol*. 2006;8:33–35.  
19. Land J, Rutgers A, Kallenberg CGM. Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody. *Nephrol Dial Transplant*. 2014;29:739–745.  
20. Jennette JC, Falk RJ. Pathogenesis of antineutrophil cytoplasmic autoantibody-mediated disease. *Nat Rev Rheumatol*. 2014;10:463–473.  
21. Erdrbrugger U, Hellmark T, Bunch DO, et al. Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimeras. *Kidney Int*. 2006;69:1799–1805.  
22. Roth AJ, Ooi JD, Hess JJ, et al. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. *J Clin Invest*. 2013;123:1773–1783.  
23. Xiao H, Schreiber A, Heeringa P, et al. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. *Am J Pathol*. 2007;170:52–64.
24. Xing G, Chen M, Liu G, et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. *J Clin Immunol*. 2009;29:282–291.

25. Gou S, Yuan J, Wang C, et al. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. *Clin J Am Soc Nephrol*. 2013;8:1884–1891.

26. Ingram G, Loveless S, Howell OW, et al. Complement activation in multiple sclerosis plaques: an immunohistochemical analysis. *Acta Neuropathol Commun*. 2014;2:53.

27. Hafler JP, Maier LM, Cooper JD, et al. CD226 Gly307Ser association with multiple autoimmune diseases. *Genes Immun*. 2009;10:5–10.

28. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature*. 2007;447:661–678.

29. Dardalhon V, Schubart AS, Reddy J, et al. CD226 is specifically expressed on the surface of Th1 cells and regulates their expansion and effector functions. *J Immunol*. 2005;175:1558–1565.

30. Wieczorek S, Hoffjan S, Chan A, et al. Novel association of the CD226 (DNAM-1) Gly307Ser polymorphism in Wegener’s granulomatosis and confirmation for multiple sclerosis in German patients. *Genes Immun*. 2009;10:591–595.